CYRX - Cryoport: Unfairly Punished Valuation Update Shows 45% Upside

• Cryoport looks well-positioned to benefit from macroeconomic crosscurrents that are driving value in biological logistics.
• The company is now supporting 69 Phase 3 clinical trials, evidencing a tide of regulatory momentum yet to be priced in.
• We see a fair value of $96 across a range of robust valuation measures, which implies respectable upside potential.
• Downside risks appear to be a slight disconnect from CYRX's share price and its top-line fundamentals.
• Here we cover all of the moving parts in the investment debate for the benefit of investors' own reasoning.

For further details see: